Method Meta-analysis
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
Systematic reviews are a way of bringing together similar clinical trials. Meta-analysis is a way of putting results or data from these trials together to work out whether treatments work, and network meta-analysis helps us decide which treatments work best.
Working alongside trial teams, we are developing new and improved ways of planning and doing these systematic reviews and meta-analyses, so that we can find out which treatments are best for patients quickly and reliably. Sometimes, treatments work better in some patients than in others, so we are also collecting more detailed data and developing reliable methods to explore this. We are developing better statistical techniques for doing all types of meta-analysis and network meta-analysis. To help others to use our new methods of doing things, we are writing user-friendly software, preparing guidance, and giving tutorials and training courses.
Working alongside trial teams, we are developing new and improved ways of planning and doing these systematic reviews and meta-analyses, so that we can find out which treatments are best for patients quickly and reliably. Sometimes, treatments work better in some patients than in others, so we are also collecting more detailed data and developing reliable methods to explore this. We are developing better statistical techniques for doing all types of meta-analysis and network meta-analysis. To help others to use our new methods of doing things, we are writing user-friendly software, preparing guidance, and giving tutorials and training courses.
Technical Summary
Systematic review and meta-analysis are essential tools for rigorously evaluating the effects of therapies, particularly integrating our trial results with those of other groups, and informing the design of our trials. This programme develops the methodology underpinning systematic reviews and meta-analyses, applies it in high-quality reviews relevant to our trials, and disseminates it to the scientific community. Interaction between systematic reviewers, methodologists and trialists is fundamental to these endeavours.
We have particular experience and an international reputation in the conduct of large collaborative systematic reviews and meta-analyses based individual participant data (IPD). Over more than 20 years, these have influenced the treatment of patients globally, and moreover, the data have been used to investigate methodological issues and develop robust solutions. However, such IPD meta-analyses are time- and resource-intensive, so a key aim is to establish when they are most needed to answer clinical questions reliably. Conversely, if aggregate data approaches are to provide a robust and speedier alternative, we need to move beyond the current methods of doing these, in order to limit the inherent biases.
With some clinical areas moving rapidly, there can be multiple trials comparing different treatments to one or more standard. This means that there is sometimes little opportunity for direct comparisons, so we also need the most robust and timely methods for network meta-analysis. We refer to pairwise meta-analysis (directly comparing two treatments) as MA and network meta-analysis (directly and indirectly comparing many treatments) as NMA.
In this area, we benefit from the arrival of new senior staff in 2017, which has substantially broadened our expertise in statistical modelling for MA and NMA. Our future plans will continue to integrate this expertise into our ongoing programme of work. For example, we will develop and implement state-of-the-art methodology in MA and NMA of time-to-event outcomes based on individual participant data (IPD), informing overall and stratified treatment decisions, while allowing for complexities in the design of the component trials, heterogeneity between trials, and inconsistency between direct and indirect evidence.
Our overall philosophy is to use the simplest methods that can be shown to be valid (often by methodological comparison with more complex methods), and wherever possible to work prospectively and collaboratively to reduce bias, increase the timeliness of our reviews, and achieve greater impact.
Our research covers four priority areas:
1. Beyond standard systematic reviews – developing review methods that move beyond standard approaches and using them to perform high-quality and challenging reviews
2. Determining methods to assess which participants benefit most from treatments in pairwise and network meta-analysis
3. Choosing and building appropriate models for in pairwise and network meta-analysis
4. Guidance and tools to increase impact of our meta-analysis methods
We have particular experience and an international reputation in the conduct of large collaborative systematic reviews and meta-analyses based individual participant data (IPD). Over more than 20 years, these have influenced the treatment of patients globally, and moreover, the data have been used to investigate methodological issues and develop robust solutions. However, such IPD meta-analyses are time- and resource-intensive, so a key aim is to establish when they are most needed to answer clinical questions reliably. Conversely, if aggregate data approaches are to provide a robust and speedier alternative, we need to move beyond the current methods of doing these, in order to limit the inherent biases.
With some clinical areas moving rapidly, there can be multiple trials comparing different treatments to one or more standard. This means that there is sometimes little opportunity for direct comparisons, so we also need the most robust and timely methods for network meta-analysis. We refer to pairwise meta-analysis (directly comparing two treatments) as MA and network meta-analysis (directly and indirectly comparing many treatments) as NMA.
In this area, we benefit from the arrival of new senior staff in 2017, which has substantially broadened our expertise in statistical modelling for MA and NMA. Our future plans will continue to integrate this expertise into our ongoing programme of work. For example, we will develop and implement state-of-the-art methodology in MA and NMA of time-to-event outcomes based on individual participant data (IPD), informing overall and stratified treatment decisions, while allowing for complexities in the design of the component trials, heterogeneity between trials, and inconsistency between direct and indirect evidence.
Our overall philosophy is to use the simplest methods that can be shown to be valid (often by methodological comparison with more complex methods), and wherever possible to work prospectively and collaboratively to reduce bias, increase the timeliness of our reviews, and achieve greater impact.
Our research covers four priority areas:
1. Beyond standard systematic reviews – developing review methods that move beyond standard approaches and using them to perform high-quality and challenging reviews
2. Determining methods to assess which participants benefit most from treatments in pairwise and network meta-analysis
3. Choosing and building appropriate models for in pairwise and network meta-analysis
4. Guidance and tools to increase impact of our meta-analysis methods
Organisations
- University College London (Lead Research Organisation)
- University of Granada (Collaboration)
- Pumping Marvellous Foundation (Collaboration)
- KEELE UNIVERSITY (Collaboration)
- Hospital Reina Sofía de Córdoba (Collaboration)
- Saint Louis University (Collaboration)
- Epsom and St Helier University Hospitals NHS Trust (Collaboration)
- McMaster University (Collaboration)
- Vanderbilt University (Collaboration)
- Somerset NHS Foundation Trust (Collaboration)
- Massachusetts General Hospital (Collaboration)
- Public Assistance - Hospitals of Paris (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- University of Paris (Collaboration)
- Ghent University Hospital (Collaboration)
- University of Copenhagen (Collaboration)
- University of Malaya (Collaboration)
- Deakin University (Collaboration)
- Circolo Hospital and Macchi Foundation (Collaboration)
- Akershus University Hospital (Collaboration)
- University of Twente (Collaboration)
- Saint Michael's Hospital (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- University of Maryland, College Park (Collaboration)
- Radboud University Nijmegen Medical Center (Collaboration)
- University of Lille (Collaboration)
- Yale University (Collaboration)
- University Hospital of Valme (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- Ann Arbor VA Medical Center (Collaboration)
- University of California (Collaboration)
- University of Sydney (Collaboration)
- Umea University (Collaboration)
- Albert Schweitzer Ziekenhuis (Collaboration)
- Kiel University (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- University of Southern California (Collaboration)
- Guy's and St Thomas' NHS Foundation Trust (Collaboration)
- UNIVERSITY OF LEEDS (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- University of Bristol (Collaboration)
- Beneficência Portuguesa de São Paulo (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- Genentech, Inc (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- AstraZeneca (United Kingdom) (Collaboration)
- Hospital Ramón y Cajal (Collaboration)
- Regeneron Pharmaceuticals, Inc. (Collaboration)
- N.N. Alexandrov National Cancer Centre of Belarus (Collaboration)
- University Hospital Erlangen (Collaboration)
- Institute of Health Carlos III (Collaboration)
- Cornell University (Collaboration)
- UNIVERSITY OF YORK (Collaboration)
- University Hospital La Princesa (Collaboration)
- European Organisation for Research and Treatment of Cancer (EORTC) (Collaboration)
- Camden and Islington NHS Foundation Trust (Collaboration)
- University of Connecticut (Collaboration)
- THE CHRISTIE NHS FOUNDATION TRUST (Collaboration)
- Turku University Hospital (Collaboration)
- University of Pennsylvania (Collaboration)
- University Medical Center Utrecht (UMC) (Collaboration)
- Fudan University (Collaboration)
- University of Côte d'Azur (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Li Ka Shing Foundation (Collaboration)
- George Institute for Global Health (Collaboration)
- Hebrew University of Jerusalem (Collaboration)
- Sapienza University of Rome (Collaboration)
- University of Paris - Descartes (Collaboration)
- QUEEN'S UNIVERSITY BELFAST (Collaboration)
- University of Melbourne (Collaboration)
- Berry Consultants LLC (Collaboration)
- University of Chicago Medical Center (Collaboration)
- UNIVERSITY HOSPITALS BRISTOL AND WESTON NHS FOUNDATION TRUST (Collaboration)
- University of Bern (Collaboration)
- NewYork–Presbyterian Hospital (Collaboration)
- University of Toronto (Collaboration)
- UNIVERSITY OF BRITISH COLUMBIA (Collaboration)
- Monash University (Collaboration)
- Ministry of Health (Collaboration)
- Health Data Research UK (Collaboration)
- Hospital de Sant Pau (Collaboration)
- Karolinska University Hospital (Collaboration)
- Sanofi (Collaboration)
- Hospital Universitario Puerta de Hierro (Collaboration)
- Albert Ludwig University of Freiburg (Collaboration)
- World Health Organization (WHO) (Collaboration)
- University College London (Collaboration)
- University of Groningen (Collaboration)
- BARTS HEALTH NHS TRUST (Collaboration)
- Necker-Enfants Malades Hospital (Collaboration)
- University of Western Australia (Collaboration)
- Peking University (Collaboration)
- Maastricht University (UM) (Collaboration)
- University of Ioannina (Collaboration)
- Queen's Medical Center (Collaboration)
- Saarland University (Collaboration)
- University of Würzburg (Collaboration)
People |
ORCID iD |
Publications
Adams R
(2021)
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.
in Cancer treatment reviews
Advanced Bladder Cancer (ABC) Meta-Analysis Collaborators Group
(2022)
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
in European urology
Buckman JEJ
(2021)
The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis.
in Psychological medicine
Buckman JEJ
(2021)
Is social support pre-treatment associated with prognosis for adults with depression in primary care?
in Acta psychiatrica Scandinavica
Buckman JEJ
(2023)
Predicting prognosis for adults with depression using individual symptom data: a comparison of modelling approaches.
in Psychological medicine
Chiocchia V
(2023)
The complexity underlying treatment rankings: how to use them and what to look at
in BMJ Evidence-Based Medicine
Claxton L
(2022)
Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation.
in Health technology assessment (Winchester, England)
Evrenoglou T
(2022)
Network meta-analysis of rare events using penalized likelihood regression
in Statistics in Medicine
Faron M
(2021)
Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction.
in European journal of cancer (Oxford, England : 1990)
Related Projects
| Project Reference | Relationship | Related To | Start | End | Award Value |
|---|---|---|---|---|---|
| MC_UU_00004/01 | 01/04/2021 | 31/03/2026 | £5,186,000 | ||
| MC_UU_00004/02 | Transfer | MC_UU_00004/01 | 01/04/2021 | 31/03/2026 | £4,446,000 |
| MC_UU_00004/03 | Transfer | MC_UU_00004/02 | 01/04/2021 | 31/03/2026 | £4,999,000 |
| MC_UU_00004/04 | Transfer | MC_UU_00004/03 | 01/04/2021 | 31/03/2026 | £5,315,000 |
| MC_UU_00004/05 | Transfer | MC_UU_00004/04 | 01/04/2021 | 31/03/2026 | £3,107,000 |
| MC_UU_00004/06 | Transfer | MC_UU_00004/05 | 01/04/2021 | 31/03/2026 | £2,889,000 |
| MC_UU_00004/07 | Transfer | MC_UU_00004/06 | 01/04/2021 | 31/03/2026 | £2,369,000 |
| MC_UU_00004/08 | Transfer | MC_UU_00004/07 | 01/04/2021 | 31/03/2026 | £2,270,000 |
| MC_UU_00004/09 | Transfer | MC_UU_00004/08 | 01/04/2021 | 31/03/2026 | £2,160,000 |
| Guideline Title | Covid Guidelines India |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) CMGIG guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) ERS guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | IDSA Guidelines on the Treatment and Management of Patients with COVID-19 |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) IDSA guideline 2022 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults) |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) NHS guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Therapeutics and COVID-19: Living Guideline. 6 July 2021 |
| Description | Anti-IL6 COVID-19 SR (PMID:34228774) WHO guideline 2021 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/ |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.6.2021 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2021 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.3.2022 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2021) |
| Description | Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/ |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2022) |
| Description | Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Bladder Neo CT IPD (PMID: 15939524) ESMO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 6.2021 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2021 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 3.2022 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical Practice Guideline GU-013 Version 6 (Muscle Invasive Bladder Cancer) (2021) |
| Description | Bladder Neo CT IPD (PMID:15846746) AHS Guideline 2021 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021 |
| Description | Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi... |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021 |
| Description | Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi... |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
| Description | Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2022 (1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2023 (1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2022 (1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2023 (1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
| Description | Cervix CTRT SR (PMID: 16034873) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update |
| Description | Cervix Neo CT IPD (PMID: 15106161) ASCO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Cancer of the Uterine Cervix |
| Description | Cervix Neo CT SR (PMID:23235641) AHS guideline 2021 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gyne004-cervical.pdf |
| Guideline Title | Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update |
| Description | Cervix Neo CT SR (PMID:23235641) ASCO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021 |
| Description | Cervix Neo CT SR (PMID:23235641) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi... |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022 |
| Description | Cervix Neo CT SR (PMID:23235641) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie endometrriumkarzinom V2.0 (2022) |
| Description | Endometrial CT SR (PMID: 22895938) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1 2022. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2022 (V1) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
| Description | Lung Adj CT IPD (PMID:25730344) ASCO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
| Description | Lung CT 95 IPD (PMID:7580546) ASCO guideline stage I-III NSCLC 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023 |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung PORT IPD (PMID: 9690404) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update |
| Description | Lung PORT IPD (PMID: 9690404; 23453644) ASCO guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung SC IPD (PMID: 18678835) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung SC IPD (PMID: 25730344) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022) |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v1.2022. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v1.2023. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinienprogramm onkologie. Diagnostik und therapie des Ösophaguskarzinoms v3.0 2021 |
| Description | Oesophagus RT IPD (PMID:16235286) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/leitlinien/oesophaguskarzinom/ |
| Guideline Title | Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. V3.1 (2022) |
| Description | Oesophagus RT IPD (PMID:16235286) GGPO guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 1.2022 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2022 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 5.2022 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2022 (v5) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2021) |
| Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Local Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) AHS guideline 2021 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu012-local-prostate.p... |
| Guideline Title | Local Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) AHS guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022) |
| Description | Prostate Artistic AD (PMID: 33002431) AUA/ASTRO guideline 2022 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2021) |
| Description | Prostate Artistic AD (PMID: 33002431) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/prostate-cancer/ |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate Artistic AD (PMID: 33002431) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinie Prostatakarzinom v6.2 2021 |
| Description | Prostate Artistic AD (PMID: 33002431) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.2.2022 Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) NCCN guideline 2021 V2 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) NCCN guideline 2023 V1 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate CT SR (PMID: 26718929) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinie Prostatakarzinom v6.2 2021 |
| Description | Prostate CT SR (PMID: 26718929) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.2.2022 Prostate Cancer |
| Description | Prostate CT SR (PMID: 26718929) NCCN guideline 2021 V2 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer |
| Description | Prostate CT SR (PMID: 26718929) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer |
| Description | Prostate CT SR (PMID: 30826218) NCCN guideline 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2021) |
| Description | Prostate Network AD (PMID: 29788164) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/prostate-cancer/ |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate Network AD (PMID: 29788164) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer |
| Description | Prostate RT AD (PMID: 30826218) CUA guideline 2022 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2021) |
| Description | Prostate RT AD (PMID: 30826218) EAU guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://uroweb.org/guideline/prostate-cancer/ |
| Guideline Title | EAU Guideline: Prostate Cancer (2022) |
| Description | Prostate RT AD (PMID: 30826218) EAU guideline 2022 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Leitlinie Prostatakarzinom v6.2 2021 |
| Description | Prostate RT AD (PMID: 30826218) GGPO guideline 2021 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v2.2022 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2021 (V2) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2021 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2021 (V2) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2022 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2022 (V2) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Description | NIHR Development and Skills Enhancement Award |
| Amount | £34,926 (GBP) |
| Funding ID | NIHR301653 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 03/2022 |
| Description | TMRP Doctoral Training Programme |
| Amount | £2,518,806 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2026 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | Circolo Hospital and Macchi Foundation |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | European Organisation for Research and Treatment of Cancer (EORTC) |
| Country | Belgium |
| Sector | Charity/Non Profit |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | N.N. Alexandrov National Cancer Centre of Belarus |
| Country | Belarus |
| Sector | Private |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | NewYork-Presbyterian Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | Saarland University |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | Saint Louis University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | Sapienza University of Rome |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | The Christie NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University Hospital Erlangen |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University of Connecticut |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University of Kiel |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials |
| Organisation | University of Southern California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision |
| Collaborator Contribution | Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 34802798) |
| Start Year | 2017 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Albert Schweitzer Hospital |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Ann Arbor VA Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Beneficência Portuguesa de São Paulo |
| Country | Brazil |
| Sector | Charity/Non Profit |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Berry Consultants LLC |
| Country | United States |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Genentech, Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Ghent University Hospital |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Health Data Research UK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hebrew University of Jerusalem |
| Department | Hebrew University Hadassah Medical School |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hospital Ramón y Cajal |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hospital Reina Sofía de Córdoba |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hospital Universitario Puerta de Hierro |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Hospital de Sant Pau |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Karolinska University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Ministry of Health |
| Country | Malaysia |
| Sector | Public |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Department | INSERM U1153 (Center for Epidemiology and Biostatistics) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Necker-Enfants Malades Hospital |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Public Assistance - Hospitals of Paris |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Queen's Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Regeneron Pharmaceuticals, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Sanofi |
| Department | Genzyme Corporation |
| Country | United States |
| Sector | Private |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | Turku University Hospital |
| Country | Finland |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University Hospital La Princesa |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University Hospital of Valme |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University Hospitals Bristol and Weston NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University Medical Center Utrecht (UMC) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Chicago Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Groningen |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Malaya |
| Country | Malaysia |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Melbourne |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Oxford |
| Department | Nuffield Department of Population Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Paris |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Organisation | World Health Organization (WHO) |
| Country | Global |
| Sector | Public |
| PI Contribution | Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript |
| Collaborator Contribution | Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision |
| Impact | 1 protocol, and 1 paper (PMID: 35076012), 1 guideline |
| Start Year | 2021 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | Barts Health NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | Queen Mary University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | University College London |
| Department | Lungs for Living Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review |
| Organisation | University of Leicester |
| Department | Respiratory Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design of the review; advised on methodology and contributed to and approved the final manuscript |
| Collaborator Contribution | Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript |
| Impact | 1 protocol, and 1 paper (PMID: 34404753) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | Pumping Marvellous Foundation |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | Somerset NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | University of Leeds |
| Department | Leeds School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | University of Maryland |
| Department | School of Medicine Maryland |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation |
| Organisation | University of York |
| Department | Centre for Reviews and Dissemination (CRD) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report |
| Impact | 1 protocol, and 1 paper (PMID: 35076012) |
| Start Year | 2018 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Akershus University Hospital |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Albert Schweitzer Hospital |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Cornell University |
| Department | Weill Cornell Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Fudan University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | George Institute for Global Health |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | McMaster University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Peking University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Radboud University Nijmegen Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Umea University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Copenhagen |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Côte d'Azur |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Lille |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Twente |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Western Australia |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | University of Wurzburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis |
| Organisation | Yale University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | 1 protocol and 1 SAP |
| Start Year | 2017 |
| Description | Dealing with Missing Data in an IPD Meta-analysis (Chapter 18). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Maastricht University (UM) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Co-authored the chapter |
| Collaborator Contribution | Co-authored the chapter. One partner led writing the chapter and one was co-editor of book |
| Impact | 1 book chapter (Chapter 18) |
| Start Year | 2015 |
| Description | Dealing with Missing Data in an IPD Meta-analysis (Chapter 18). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | University Medical Center Utrecht (UMC) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Co-authored the chapter |
| Collaborator Contribution | Co-authored the chapter. One partner led writing the chapter and one was co-editor of book |
| Impact | 1 book chapter (Chapter 18) |
| Start Year | 2015 |
| Description | Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study |
| Organisation | Deakin University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review |
| Collaborator Contribution | Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review |
| Impact | 1 protocol, and 1 paper (PMID: 36219622) |
| Start Year | 2021 |
| Description | Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review |
| Collaborator Contribution | Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review |
| Impact | 1 protocol, and 1 paper (PMID: 36219622) |
| Start Year | 2021 |
| Description | Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study |
| Organisation | Queen's University Belfast |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review |
| Collaborator Contribution | Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review |
| Impact | 1 protocol, and 1 paper (PMID: 36219622) |
| Start Year | 2021 |
| Description | Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study |
| Organisation | University of Sydney |
| Department | NHMRC Clinical Trials Centre |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review |
| Collaborator Contribution | Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review |
| Impact | 1 protocol, and 1 paper (PMID: 36219622) |
| Start Year | 2021 |
| Description | IW advisor to Orestis Efthimiou grant |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Advised on development and submission of successful research grant proposal to Swiss National Science Foundation (SNSF). Collaborated on two papers. |
| Collaborator Contribution | Developed and submitted successful research grant proposal to Swiss National Science Foundation (SNSF). Collaborated on two papers. |
| Impact | Two papers published so far. |
| Start Year | 2017 |
| Description | IW collaborator on SNSF grant, PI Georgia Salanti |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Advised on development and submission of successful grant application to SNF. Collaborating on papers. |
| Collaborator Contribution | Developed and submitted successful grant application to SNF. Collaborating on papers. |
| Impact | Multi-disciplinary - epidemiology, systematic review, biostatistics. One publication on treatment hierarchy question. Future impact on conduct of network meta-analysis. |
| Start Year | 2017 |
| Description | IW in ROBIS-NMA group |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed expertise in network meta-analysis |
| Collaborator Contribution | Contributed expertise in systematic review and network meta-analysis |
| Impact | Multidisciplinary work - systematic review and biostatistics. Current outputs - two publications on methods for developing the tool. Future outputs - tool for evaluating risk of bias in a network meta-analysis, expected impact on use of network meta-analysis in health policy making |
| Start Year | 2020 |
| Description | IW in ROBIS-NMA group |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Contributed expertise in network meta-analysis |
| Collaborator Contribution | Contributed expertise in systematic review and network meta-analysis |
| Impact | Multidisciplinary work - systematic review and biostatistics. Current outputs - two publications on methods for developing the tool. Future outputs - tool for evaluating risk of bias in a network meta-analysis, expected impact on use of network meta-analysis in health policy making |
| Start Year | 2020 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | Saint Michael's Hospital |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | University of Ioannina |
| Country | Greece |
| Sector | Academic/University |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Incorporating dose effects in network meta-analysis |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings |
| Collaborator Contribution | Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback |
| Impact | 1 paper (PMID: 35042687) |
| Start Year | 2016 |
| Description | Individual participant data meta-analysis: A handbook for healthcare research (whole book) |
| Organisation | Keele University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-editor. Conceived the book concept and planned the outline. Co-authored multiple chapters |
| Collaborator Contribution | Co-editors. Conceived the book concept and planned the outline. Co-authored multiple chapters |
| Impact | 1 book [ISBN: 978-1-119-33372-2] |
| Start Year | 2015 |
| Description | Individual participant data meta-analysis: A handbook for healthcare research (whole book) |
| Organisation | University of York |
| Department | Centre for Reviews and Dissemination (CRD) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-editor. Conceived the book concept and planned the outline. Co-authored multiple chapters |
| Collaborator Contribution | Co-editors. Conceived the book concept and planned the outline. Co-authored multiple chapters |
| Impact | 1 book [ISBN: 978-1-119-33372-2] |
| Start Year | 2015 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Hospital Ramón y Cajal |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Institute of Health Carlos III |
| Country | Spain |
| Sector | Public |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | Queen Mary University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Organisation | University of Granada |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft |
| Collaborator Contribution | Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft |
| Impact | 1 protocol, and 1 paper (PMID: 34171281) |
| Start Year | 2018 |
| Description | Long term pregnancy outcomes of women with cancer following fertility preservation: A systematic review and meta-analysis |
| Organisation | Epsom and St Helier University Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Members of the research team were commented on the protocol, provided feedback and advice during the project, and commented on the final report |
| Collaborator Contribution | Development of the protocol. Performed all trial searches, completed data extraction, analysis and writing the report |
| Impact | 1 protocol (CRD42021269016) and 1 paper (PMID: 36535069) |
| Start Year | 2021 |
| Description | Multivariate Meta-analysis Using IPD (Chapter 13). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Co-authored the chapter |
| Collaborator Contribution | Co-authored the chapter. One partner led writing the chapter and was co-editor of book |
| Impact | 1 book chapter (Chapter 13) |
| Start Year | 2015 |
| Description | Multivariate Meta-analysis Using IPD (Chapter 13). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Keele University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-authored the chapter |
| Collaborator Contribution | Co-authored the chapter. One partner led writing the chapter and was co-editor of book |
| Impact | 1 book chapter (Chapter 13) |
| Start Year | 2015 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | Albert Ludwig University of Freiburg |
| Department | Faculty of Medicine |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | Li Ka Shing Foundation |
| Country | Hong Kong |
| Sector | Charity/Non Profit |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | University of Bern |
| Department | Institute of Social and Preventive Medicine |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | University of Ioannina |
| Country | Greece |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions |
| Organisation | University of Paris - Descartes |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Collaborator Contribution | Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript |
| Impact | 1 paper (PMID: 34689743) |
| Start Year | 2017 |
| Description | Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Keele University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led writing of chapter. Co-editor of book |
| Collaborator Contribution | Co-authored the chapter, two partners co-editors of book |
| Impact | 1 book chapter (Chapter 2) |
| Start Year | 2015 |
| Description | Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Queen's University Belfast |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led writing of chapter. Co-editor of book |
| Collaborator Contribution | Co-authored the chapter, two partners co-editors of book |
| Impact | 1 book chapter (Chapter 2) |
| Start Year | 2015 |
| Description | Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led writing of chapter. Co-editor of book |
| Collaborator Contribution | Co-authored the chapter, two partners co-editors of book |
| Impact | 1 book chapter (Chapter 2) |
| Start Year | 2015 |
| Description | Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | University of York |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Led writing of chapter. Co-editor of book |
| Collaborator Contribution | Co-authored the chapter, two partners co-editors of book |
| Impact | 1 book chapter (Chapter 2) |
| Start Year | 2015 |
| Description | ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP. |
| Start Year | 2019 |
| Description | ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP. |
| Start Year | 2019 |
| Description | ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis |
| Organisation | University of Leeds |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP. |
| Collaborator Contribution | Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript |
| Impact | I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP. |
| Start Year | 2019 |
| Description | Sharing individual participant data: through a systematic reviewer lens |
| Organisation | University of York |
| Department | Centre for Reviews and Dissemination (CRD) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Conceived the idea for the article and drafted the manuscript, approved the final manuscript. |
| Collaborator Contribution | Input into the manuscript and approved the final manuscript |
| Impact | 1 manuscript [doi.org/10.1186/s13063-021-05787-4] |
| Start Year | 2021 |
| Description | The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Co-author of the chapter |
| Collaborator Contribution | Co-authors of the chapter. One partner led writing the chapter and co-editor of book |
| Impact | 1 book chapter (Chapter 5) |
| Start Year | 2015 |
| Description | The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | Keele University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-author of the chapter |
| Collaborator Contribution | Co-authors of the chapter. One partner led writing the chapter and co-editor of book |
| Impact | 1 book chapter (Chapter 5) |
| Start Year | 2015 |
| Description | The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research |
| Organisation | University Medical Center Utrecht (UMC) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Co-author of the chapter |
| Collaborator Contribution | Co-authors of the chapter. One partner led writing the chapter and co-editor of book |
| Impact | 1 book chapter (Chapter 5) |
| Start Year | 2015 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | Camden and Islington NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Exeter |
| Department | College of Medicine and Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Exeter |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Pennsylvania |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | University of York |
| Department | Department of Health Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis |
| Organisation | Vanderbilt University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report. |
| Collaborator Contribution | Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report |
| Impact | 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056) |
| Start Year | 2019 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | Keele University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | University of Bern |
| Department | Institute of Social and Preventive Medicine |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Description | Using individual participant data to improve network meta-analysis projects |
| Organisation | University of York |
| Department | Centre for Reviews and Dissemination (CRD) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Members of the research team provided feedback and advice during the project, and commented on the final manuscript |
| Collaborator Contribution | Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript |
| Impact | 1 paper (PMID: 35948411) |
| Start Year | 2022 |
| Title | mvmeta update |
| Description | Update of mvmeta: multivariate meta-analysis |
| Type Of Technology | Software |
| Year Produced | 2022 |
| Open Source License? | Yes |
| Impact | The original software has been used to improve precision and reduce bias in several published meta-analysis, and is an essential part of the widely used "network" package for performing network meta-analysis in Stata. The update has no impact as yet. |
| URL | https://ideas.repec.org/c/boc/bocode/s456970.html |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A series of Tweets directed at different audiences e.g. systematic reviewers; clinicians, and making use of collaborators influential on twitter. News story on MRC CTU@ UCL website and STOPCAPM1 website |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Response to an opinion piece (published in Nature) critical of aggregate data meta-analysis for COVID 19, to demonstrate how a collaborative and prospective approach to meta-analysis can produce timely, reliable and thorough aggregate data meta-analysis in COVID 19. |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A short questionnaire was emailed to a range of Systematic Review experts, asking them to read the manuscript and then respond as to whether they liked it or not and why, and whether they thought they would use the methods or not and why. This helped identify barriers and concerns that will influence future engagement and research on FAME |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Submitted a nomination to the Cochrane Reward Prize to demonstrate how a collaborative and prospective approach to meta-analysis can produce timely, reliable and thorough aggregate data meta-analysis in COVID 19, thereby reducing research waste. The submission made it to the second round of judging. |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation at meeting of Methodologists to describe the considerable dissemination activities that took place around the publication of the FAME manuscript |
| Year(s) Of Engagement Activity | 2021 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | JT and SB invited to host a live webinar for Cochrane Methods Support Unit. 'How can the framework for prospective, adaptive meta-analysis (FAME) be used to improve the quality of Cochrane reviews?' (9 March 2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Invited to contribute to Cochrane's response to the WHO consultation 'World Health Assembly Resolution on strengthening clinical trials'. Focussing on how FAME Framework can help to reduce research waste. |
| Year(s) Of Engagement Activity | 2022 |
| Description | A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The MiM meeting is a seminar series bringing together researchers who work in meta-analysis methodology. Presenting this work to this audience was an opportunity to promote the value of the approach taken to this review and the benefits it brings. It sparked interest and discussion among those keen to adapt their own approach to meta-analysis in similar ways |
| Year(s) Of Engagement Activity | 2021 |
| Description | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Twitter posts (story and thread); News story on MRC CTU @ UCL website |
| Year(s) Of Engagement Activity | 2022 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The world evidence based healthcare day 2021 was a call to the global evidence community to share their experiences, expertise and stories on infodemic management in the wake of the COVID pandemic. It is a global initiative that aims to raise awareness of the need for better evidence to inform healthcare policy, practice and decision making in order to improve health outcomes globally. It also provides an opportunity to participate in debate and to celebrate the impact of individuals and organisations worldwide, recognising the work of dedicated researchers, policymakers and health professionals in improving health outcomes. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented the findings of the IL6 review to the MRCCTU staff as part of the lunchtime seminar series, and answered queries both about the methods used, results and their impact and meaning. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A press release to coincide with the publication of this work and the accompanying WHO Guideline was written and disseminated in conjunction with Kings College London, University of Bristol, UCL and WHO teams. It was picked up in a number of media outlets, including Bloomberg, Reuters, Daily Mail, NBC News, AFP, and dozens of international titles |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Presented the preliminary results of the IL-6 meta-analysis to the WHO Guideline development group and answered questions and queries on the methods and results. This is the group responsible for deciding whether new WHO guidelines will recommend a treatment or not based on the evidence available to them |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The MiM meeting is a seminar series bringing together researchers who work in meta-analysis methodology. Presenting this work to this audience was an opportunity to promote the value of the approach taken to this review and the benefits it brings. It sparked interest and discussion among those keen to adapt their own approach to meta-analysis in similar ways |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Used a series of tweet to promote the key messages of the review as well as aspects of the methodology used to highlight the value in the approach. The tweets were retweeted, and quoted by more than 60 news outlets. The Altmetric score is 871, putting the article in the top 5% of all research outputs, largely driven by activity on Twitter. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This summarised the process and merits of the approach taken to this piece of research, the value of collaboration and how extensive and efficient the process was. It was included on the MRC CTU website and promoted on Twitter |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.mrcctu.ucl.ac.uk/our-research/methodology/meta-analysis/blog-interlukin-6-antagonists-im... |
| Description | Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Pre-publication manuscript was shared with Public Health England. as Tocilizumab, an interleukin-6 receptor antagonist that was shown to reduce mortality for patients hospitalised with COVID-19 and stores in England were running low. The paper provided evidence that Sarilumab (an alternative interleukin-6 receptor antagonist) had similar mortality benefits |
| Year(s) Of Engagement Activity | 2022 |
| Description | Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Tweets were written and sent publicising the findings of this paper |
| Year(s) Of Engagement Activity | 2022 |
| Description | Biarritz NMA course |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A 3-day course on network meta-analysis was delivered to 30 participants, mostly from Europe. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.cer-methods.com/2021/12/09/nmacourse/ |
| Description | Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Thread of short posts taking readers through the paper step by step. This series of posts was posted both on Twitter and Mastodon |
| Year(s) Of Engagement Activity | 2023 |
| Description | Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | After engagement with the PPI members, authors wrote (with PPI members support) content for a news story hosted the MRC CTU website and an associated twitter thread that was widely shared. After this content was live, the authors have since been contacted by two separate researchers asking for clarification on the method and advice implementing the method in their own studies |
| Year(s) Of Engagement Activity | 2022 |
| Description | Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Two of the authors (PG, DF) engaged with two patient and public representatives to help improve dissemination of the methodology and reach a wider audience. The PPI members contributed to writing and editing content to be shared on social platforms. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference paper presentation at the Society for Clinical Trials Annual Meeting for both an in-person and virtual audience. The talk and paper won the Thomas Chalmer's Award from the Society |
| Year(s) Of Engagement Activity | 2022 |
| Description | Individual Participant Data Meta-analysis: A Handbook for Healthcare Research |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Contributed to website aimed at promoting the book |
| Year(s) Of Engagement Activity | 2021,2022 |
| URL | https://www.ipdma.co.uk/textbook |
| Description | Individual participant data meta-analysis: A handbook for healthcare research |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Tweets announcing publication through the MRC CTU Twitter account |
| Year(s) Of Engagement Activity | 2021 |
| Description | Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | A blog post from the co-author discussing the research in the context of her personal experience as a pregnant woman at risk of iron deficiency anaemia. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.qmul.ac.uk/media/news/2021/smd/pregnant-women-need-more-information-and-options-for-trea... |
| Description | Meta-analyses based on summary data can provide timely, thorough and reliable evidence: don't dismiss them yet |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A twitter thread summarising the rationale for this work and the key messages was written by one of the authors. To date, this has had over 300 engagements. The journal, with over 300K followers also widely shared the work and created an infographic with a quote from the paper that has been retweeted widely. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Meta-analyses based on summary data can provide timely, thorough and reliable evidence: don't dismiss them yet |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The work in this paper was presented during the national 2022 'Meta-Analysis in Medicine' meeting (that had invited international colleagues) of statisticians who specialise in meta-analysis, including some PhD students. The talk sparked numerous questions from the audience. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Presentation: 'metan: a Stata package for performing aggregate-data meta-analysis' |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | The updated version of the STATA program METAN was presented at the UCL-wide workshop "Writing methodological software for statistical applications in health". Presentation entitled "metan: a Stata package for performing aggregate-data meta-analysis" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Sharing individual participant data: through a systematic reviewer lens |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Tweets and new story on MRC CTU @ UCL website |
| Year(s) Of Engagement Activity | 2021 |